ライフサイエンスコーパス: PGA

1 PGA is an asthma phenotype with no evidence of increased

2 PGA is produced by the Gram-negative periodontopathogen

3 PGA is user friendly software that can facilitate decisi

4 PGA levels were triphasic; they were nondetectable at 24

5 PGA manifests as an uncoupling of airway obstruction fro

6 PGA overproduction appeared to be the result of an incre

7 PGA production was undetectable in an nhaR mutant strain

8 nduced structural perturbations in apo and 2-PGA-bound forms of TIM that are atypical of WT.

9 n-intermediate analog, 2-phosphoglycolate (2-PGA).

10 3-PGA acts synergistically with both ATP and ADP-Glc in he

11 classic regulators 3-phosphoglyceric acid (3-PGA) and inorganic phosphate (Pi) stabilize maize (Zea m

12 lly activated with 3-phosphoglyceric acid (3-PGA).

13 AGPase to the same extent as the activator 3-PGA, albeit with higher K(a) (activation constant) value

14 n both the small and large subunits--bound 3-PGA more weakly than the wild type (A(50) increased by 3

15 not always mimic the changes observed for 3-PGA.

16 In addition, extent of 3-PGA activation and extent of 3-PGA affinity were found t

17 , extent of 3-PGA activation and extent of 3-PGA affinity were found to be separate entities, mapping

18 In the presence of 3-PGA, ADP-Glc is a competitive inhibitor with respect to

19 In the presence of 3-PGA, enzyme properties of Mos(1-198)/SH2 are quite simil

20 In the absence of 3-PGA, however, the mosaic enzyme exhibits greater activit

21 Finally, in the absence of 3-PGA, inorganic phosphate, a classic inhibitor or antiact

22 In the absence of 3-PGA--with or without 5.0 mm inorganic phosphate--ADP-Glc

23 e, is a potent inhibitor in the absence of 3-PGA.

24 e-6-P and Glc-6-P is comparable to that of 3-PGA.

25 When 3-phosphoglycerate (3-PGA), the putative physiological activator, was present

26 norganic phosphate and 3-phosphoglycerate (3-PGA).

27 y enhanced catalytic activity and restored 3-PGA activation.

28 In fact, compared to 3-PGA, fructose-6-phosphate is a more efficient activator

29 equential mechanism was also followed when 3-PGA was absent, but product inhibition patterns changed

30 r the binding interactions associated with 3-PGA in which allosteric activators and inorganic phospha

31 rtensive use (OR, 7.05 [CI, 3.05 to 16.31]), PGA score greater than 1 (OR, 4.02 [CI, 1.84 to 8.82]),

32 lutaminase-asparaginase from Pseudomonas 7A (PGA) was investigated using structural, mass spectrometr

33 The addition of 0.9% PGA caused 7S, 11S, daidzein and genistein to coacervate

34 raction (SPF) following incubation with 0.9% PGA for 1h.

35 the 7S and 11S proteins into the SPF by 0.9% PGA.

36 A PGA response was achieved by 155 (47.1%) of 329 patients

37 ) [corrected] in the 100 mg group achieved a PGA response, compared with 7 patients (4%) in the place

38 ) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), a

39 lycaprolactone sheet seeded with SMCs, and a PGA sheet seeded with fibroblast, were wrapped in turn o

40 A pipeline with an R package, assigned as a PGA utility, was developed that enables automated treatm

41 nt of wild-type biofilms with dispersin B, a PGA-degrading enzyme, rendered them sensitive to detachm

42 t week 40, the proportion of patients with a PGA score of 0 or 1 remained significantly higher in the

43 t week 16, the proportion of patients with a PGA score of 0 or 1 was significantly higher in each gus

44 n metrics, such as peak ground acceleration (PGA) and peak ground velocity (PGV), we find that correc

45 sule mutant, and a poly-N-acetylglucosamine (PGA) mutant.

46 patients (58%) in the 100 mg group achieved PGA responses, compared with 11 patients (7%) in the pla

47 52, 79.2% of q4-wk-treated patients achieved PGA "clear/minimal" compared with 41.6% and 6.0% of q12-

48 s. 4.3% of placebo-treated patients achieved PGA "clear/minimal," and 80.7% vs. 4.5%, respectively, a

49 er imputation compared proportions achieving PGA "clear/minimal" (weeks 12 and 52) and >/=75% improve

50 thick fabricated from poly-l-glutamic acid (PGA) and poly-l-lysine (PLL) can be loaded, post-fabrica

51 hagocytic gamma-linked poly-d-glutamic acid (PGA) capsule and two binary toxins, complexes of protect

52 The poly-gamma-glutamic acid (PGA) capsule produced by Bacillus anthracis is composed

53 oly-l-lysine (PLL) and poly-l-glutamic acid (PGA) in their non-alpha-helical states.

54 rmidis secretes poly-gamma-DL-glutamic acid (PGA) to facilitate growth and survival in the human host

55 ently linked to poly(alpha)-L-glutamic acid (PGA) via reducible disulfide and acid-sensitive hydrazon

56 kin prick test for poly-gamma-glutamic acid (PGA) which is a component of jellyfish stings was negati

57 sponsive biodegradable poly-L-glutamic acid (PGA)-fluocinolone acetonide (FLUO) conjugate that allows

58 , covalently linked to poly-l-glutamic acid (PGA).

59 tide composed of poly-gamma-D-glutamic acid (PGA).

60 as carboxyl content (polygalacturonic acid (PGA) > citric acid (CA) > galacturonic acid (GA)).

61 P was first conjugated to polyglutamic acid (PGA) to form anionic PGA-CDDP which was electrostaticall

62 ain viability relative to polyglycolic acid (PGA) non-woven mesh controls.

63 re subsequently seeded on polyglycolic acid (PGA) scaffolds or densified collagen constructs for 4 we

64 A polyglycolic acid (PGA) sheet and a polycaprolactone sheet seeded with SMCs

65 iomerically pure D- and L-pyroglutamic acid (PGA) are capable of recurring self-actuation due to rapi

66 Poly(glycolic acid) (PGA) fiber scaffolds were wrapped around the hydrogels,

67 the synthesis of the polysaccharide adhesin PGA (poly-beta-1,6-N-acetyl-d-glucosamine) of Escherichi

68 d levels of platelet/granulocyte aggregates (PGAs) are found in patients suffering from many differen

69 investigated the propylene glycol alginate (PGA)-induced coacervation of beta-conglycinin (7S), glyc

70 A pheromone trail-based genetic algorithm (PGA) was used to search globally for the optimal placeme

71 All PGAs increased MMP-1, -3, and -9.

72 All PGAs increased TIMP-3, but only unoprostone increased TI

73 h 85.0% of eyes in the prostaglandin analog (PGA) group (P < 0.001), and qualified success (IOP </=21

74 atients were receiving prostaglandin analog (PGA) monotherapy.

75 mized to either SLT or prostaglandin analog (PGA; travoprost, 0.004%).

76 ffectiveness of the prostaglandin analogues (PGAs) bimatoprost, latanoprost, and unoprostone.

77 rability of generic prostaglandin analogues (PGAs) compared with their original counterpart.

78 he "Power for Genetic Association analyses" (PGA) package which comprises algorithms and graphical us

79 of isopeptidase activity, whereas PGA(1) and PGA(2) with simple alpha,beta-unsaturated pentenones wer

80 asurements indicate that PLL (at pH = 2) and PGA (at pH = 9) exist mainly in a mixture of polyproline

81 modified Facial SASI (0.40 [0.17-0.72]), and PGA scores (0.40 [0.18-0.70]).

82 proportion of patients achieving PASI 75 and PGA response (score of 0 or 1 with >/=2 grade score redu

83 CSAMI Activity scale (0.69 [0.51-0.87]) and PGA (0.66 [0.47-0.85]), weak for the CSAMI Damage scale

84 icient at increasing complement activity and PGA formation.

85 atients with DM using the CDASI, CAT-BM, and PGA scales.

86 the horizontally acquired pgaABCD operon and PGA biosynthesis at multiple levels.

87 y higher levels of antibodies against PA and PGA than PA-PGA conjugate.

88 e report the characterization of LF, PA, and PGA levels during the course of inhalation anthrax in fi

89 In addition, we find that a PLL and PGA mixture at neutral pH is approximately 60% beta-shee

90 ctions in daily health assessment scores and PGA scores compared with baseline levels (P < 0.05).

91 here were no differences between the SLT and PGA groups in the absolute mean reduction of IOP (4.0 vs

92 symptoms, as measured by WOMAC subscales and PGA scores, was observed in all groups, with no treatmen

93 cells, whereas TGN-LVs containing the XG and PGA/RG-I epitopes fuse with the plasma membrane of both

94 innate immune cells to B. anthracis PGA and PGAs from nonpathogenic B. subtilis subsp. chungkookjang

95 d to polyglutamic acid (PGA) to form anionic PGA-CDDP which was electrostatically complexed with the

96 of human innate immune cells to B. anthracis PGA and PGAs from nonpathogenic B. subtilis subsp. chung

97 ifferentially to the PGAs, with B. anthracis PGA being least stimulatory and B. licheniformis PGA mos

98 To determine if B. anthracis PGA confers a pathogenic advantage over other PGAs, we c

99 We conclude that B. anthracis PGA is recognized less effectively by innate immune cell

100 B. anthracis PGA persisted longer in high m.w. form in monocyte and i

101 Reducing the m.w. of B. anthracis PGA reduced monocytes' cytokine responses.

102 elicited more TLR2 signal than B. anthracis PGA, but only responses to B. subtilis PGA were affected

103 elicited more TLR4 signal than B. anthracis PGA, whereas B. subtilis PGA elicited none.

104 or in subgroups based on previous use of any PGA, any non-PGA, latanoprost, or travoprost monotherapi

105 Pediatric granulomatous arthritis (PGA) has been associated with 12 different substitutions

106 erity and the Physician's Global Assessment (PGA) as a reference instrument.

107 T-BM), with the Physician Global Assessment (PGA) as the "gold standard".

108 endpoints were Physician Global Assessment (PGA) at week 4 and change from baseline to 4 weeks in th

109 recalled using the Parent Global Assessment (PGA) measure.

110 ns in which the physician global assessment (PGA) of disease activity was the dependent variable, we

111 higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to

112 lear or minimal physician global assessment (PGA) score at week 16, comparing adalimumab 0.8 mg/kg wi

113 tients with a Physician's Global Assessment (PGA) score of 0 (indicating cleared psoriasis) or 1 (ind

114 (WOMAC) index and patient global assessment (PGA) scores, and in slowing radiographic progression.

115 ssment forms, physician's global assessment (PGA), and measurement of inflammatory markers including

116 ints included physician's global assessment (PGA), time to response, response duration, and time to p

117 Index and the Physician's Global Assessment (PGA).

118 ated with the Physician's Global Assessment (PGA).

119 ement >/=10%, Physician's Global Assessment [PGA] score >/=3, and Psoriasis Area and Severity Index [

120 uboptimal (HS Physician's Global Assessment [PGA] score of moderate or worse) at weeks 28 or 31.

121 lly reduced, and it had less cell-associated PGA.

122 NOD2-associated PGA can be a multisystem disorder with significant visce

123 ocytic asthma, and paucigranulocytic asthma (PGA).

124 dditionally, interobserver agreement between PGA and PtGA scores was good (acne, kappa = 0.68; psoria

125 Specific binding between PGA and LPS was consistently detected by surface plasmon

126 acetylase catalytic activity of PgaB blocked PGA export and biofilm formation, implying that N-deacet

127 ion were similar between the two meshes, but PGA constructs had contracted significantly.

128 ic polyglycolic acid/trimethylene carbonate (PGA/TMC) barrier membrane with an increased absorption t

129 jection of debris or splintering, the chiral PGA crystals respond to internal strain with unprecedent

130 ng a PGA score of "clear" or "almost clear" (PGA response), analysed in the full analysis set (all pa

131 monoclonal antibody directed against E. coli PGA, we now demonstrate that PgaD is also needed for PGA

132 On the basis of a published dataset, PGA was employed to identify peptides, resulting in 636

133 in patients with PGA and therefore defining PGA as a potentially "steroid-insensitive" phenotype tha

134 hydrolase named dispersin B, which degrades PGA.

135 I alone is more immunogenic than PA, and DNI-PGA conjugate elicits significantly higher levels of ant

136 complement-mediated mechanisms that enhance PGA formation in human whole blood stimulated with throm

137 y, our data indicate that properdin enhances PGA formation via increased production of C5a, and that

138 For carboxyl-rich coprecipitates (Fh-PGA and Fh-CA), mineral transformations were less inhibi

139 nual search, from the marketing of the first PGA, latanoprost, in 1995 to the present.

140 nts important novel biological functions for PGA and indicates that PGA represents an excellent targe

141 ion of the pgs operon that encodes genes for PGA synthesis.

142 now demonstrate that PgaD is also needed for PGA formation.

143 ent glycosyltransferase that is required for PGA synthesis.

144 hat it forms the outer membrane secretin for PGA.

145 2) and PGD(2), or PGB(2), which differs from PGA(2) only in that its electrophilic carbon is rendered

146 our scheme for the bioproduction of UGA from PGA.

147 Furthermore, PGA protected S. epidermidis from high salt concentratio

148 cation of gamma-poly-dl-glutamic acid (gamma-PGA) as an exopolymer that increases biofilm formation,

149 Poly-gamma-glutamic acid (gamma-PGA) is an important biochemical product with a variety

150 ponsible for poly-gamma-glutamic acid (gamma-PGA) synthesis), were intentionally knocked out in the B

151 te modified poly(gamma-glutamic acid) (gamma-PGA-HEMA), generating hybrid HRP@gamma-PGA-HEMA nanopart

152 ation of these regulators as affecting gamma-PGA production and biofilm formation suggests that these

153 omestic strain was sufficient to allow gamma-PGA production.

154 In addition to controlling gamma-PGA production, ComPA and DegSU were also shown to activ

155 he genes pgsB and pgsC responsible for gamma-PGA biosynthesis were increased by 8.21- and 5.26-fold,

156 ogenase), WX-zwf, produced the highest gamma-PGA concentration (9.13 g/L), 35% improvement compared t

157 gamma-PGA-HEMA), generating hybrid HRP@gamma-PGA-HEMA nanoparticles (HRP@PGH NPs).

158 rk reports a novel approach to improve gamma-PGA through over expression of key enzymes in cofactor N

159 Production of gamma-PGA by Bacillus subtilis was known to be dependent on th

160 estic strain of B. subtilis to produce gamma-PGA was mapped to two base pairs; a single base pair cha

161 generation were over-expressed in the gamma-PGA producing strain B. licheniformis WX-02.

162 s an effective strategy to improve the gamma-PGA production in B. licheniformis.

163 Trials comparing original and generic PGAs did not show a clinically significant difference in

164 As predicted, if poly-beta-1,6-GlcNAc (PGA) mediates cohesion, metaperiodate caused biofilm dis

165 1,6-N-acetyl-D-glucosamine (beta-1,6-GlcNAc; PGA) serves as an adhesin for the maintenance of biofilm

166 dhesin poly-beta-1,6-N-acetyl-D-glucosamine (PGA) by binding to the pgaABCD mRNA leader, inhibiting p

167 dhesin poly-beta-1,6-N-acetyl-d-glucosamine (PGA).

168 ugating the capsular poly-gamma-d-glutamate (PGA) with PA to elicit the production of antibodies spec

169 extracellular polymer poly-gamma-glutamate (PGA) to confer a mucoid colony phenotype.

170 Hence, PGA can identify novel peptides and generate an HTML-bas

171 However, PGA is sometimes underestimated because of the exclusive

172 polygalacturonic acid/rhamnogalacturonan-I (PGA/RG-I) are detected in the trans-most cisternae and T

173 Importantly, PGA efficiently sheltered S. epidermidis from key compon

174 rovide precision therapies that will improve PGA clinical outcomes.

175 assessing pain and physical function, and in PGA-OA, although the improvements were modest and tanezu

176 auses an approximately threefold increase in PGA production and an approximately sevenfold increase i

177 tor prevents properdin-mediated increases in PGA formation.

178 most frequently observed features of PAP in PGA-treated eyes compared with untreated fellow eyes.

179 All physiological properdin forms increase PGA formation, but properdin tetramers are the most effi

180 ation in diseases characterized by increased PGA formation.

181 ment alternative pathway activity, increases PGA formation when added to TRAP-stimulated blood.

182 part of the innate immune system, influences PGA formation, but the mechanisms for its effects are un

183 e cohorts of PGA patients, the International PGA Registry and a Spanish cohort.

184 several phylogenetically diverse bacteria is PGA, a linear polymer of N-acetylglucosamine residues in

185 Bacillus species produce mixed d-, l-isomer PGAs.

186 n ATM mutant MCL cell line, an ATM knockdown PGA CLL cell line, and 9 ATM-deficient primary CLLs indu

187 B. subtilis PGA and B. licheniformis PGA both elicited more TLR2 signal than B. anthracis PGA

188 L-10 and TNF-alpha, whereas B. licheniformis PGA elicited all those plus IL-1beta.

189 B. licheniformis PGA elicited more TLR4 signal than B. anthracis PGA, whe

190 PGA also elicited IL-6, and B. licheniformis PGA elicited those plus IL-12p70, IL-10, IL-1beta, and T

191 Only B. licheniformis PGA induced dendritic cell maturation.

192 being least stimulatory and B. licheniformis PGA most stimulatory.

193 Longitudinal PGA severity scores were collected for acne and psoriasi

194 Our findings suggest that the LT PGA/TMC barrier membrane, used in conjunction with an al

195 ter a GBR procedure using the long-term (LT) PGA/TMC membrane and an allograft in a thermoplastic car

196 Mean PGA score at week 4 was 0.6 (SD 1.0) in the placebo grou

197 Mean PGA-OA scores decreased from 3.4 to 2.4 in the 2.5-mg gr

198 locally by leukocytes, impairs TRAP-mediated PGA formation to the same level as specific inhibition o

199 methotrexate group achieved clear or minimal PGA (p=0.083).

200 on of patients who achieved clear or minimal PGA compared with methotrexate.

201 ASI75 and 16 (41%) achieved clear or minimal PGA.

202 an's global assessment "clear" or "minimal" (PGA "clear/minimal") at week 12 were then re-randomized

203 of PAP, especially when initiating monocular PGA therapy.

204 st, patients who continued taking brand name PGAs were 28% less likely to have improved adherence (od

205 ween persons who continued to use brand-name PGAs once generic latanoprost became available and other

206 ps based on previous use of any PGA, any non-PGA, latanoprost, or travoprost monotherapies.

207 Notably, PGA was synthesized by all tested strains of S. epidermi

208 synthesis of cyclic di-GMP, an activator of PGA production.

209 We report a case of PGA in a 6-year-old girl with the NOD2 E383K gene substi

210 on of PGA may explain the rapid clearance of PGA that is observed in vivo compared to the slow cleara

211 ed merged data from 2 prospective cohorts of PGA patients, the International PGA Registry and a Spani

212 new structures of non-covalent complexes of PGA with different substrates, as well as structures of

213 This degradation of PGA may explain the rapid clearance of PGA that is obser

214 predicted that the conversion efficiency of PGA into UGA increases in a range of coefficients of dil

215 n about the uptake and intracellular fate of PGA.

216 d the primary amine content (glucosamine) of PGA.

217 res of covalent acyl-enzyme intermediates of PGA with canonical substrates (L-Asp and L-Glu) and an o

218 also revealed a conditional localization of PGA at the cell poles, the initial attachment site for b

219 ellular uptake and organelle localization of PGA in the murine macrophage-like cell line J774.2.

220 pgs operon, suggesting a second mechanism of PGA control.

221 The pipeline of PGA, aimed at being platform-independent and easy-to-use

222 confocal microscopy revealed the presence of PGA-FLUO within the epidermis, but a minimal presence in

223 rain that was deficient in the production of PGA (poly-N-acetyl-glucosamine), a biofilm matrix polysa

224 ith the reduced expression and production of PGA.

225 tions in known transcriptional regulators of PGA synthesis (Com and Deg two-component systems) as wel

226 Collectively, further understanding of PGA with a focus on the characterization, prevalence, cl

227 ne oxide inhibited the binding and uptake of PGA in these cells.

228 An extended version of PGA can predict additional candidate connections for eac

229 demonstrate that the effects of properdin on PGA formation are tightly regulated by Factor H.

230 ized controlled trials comparing an original PGA with its generic counterpart were included.

231 patient global assessment of osteoarthritis (PGA-OA) (1-5, very good to very poor) scores.

232 caused by A. actinomycetemcomitans and other PGA-producing bacteria.

233 ontinuation of use as generic forms of other PGA agents become available.

234 GA confers a pathogenic advantage over other PGAs, we compared the responses of human innate immune c

235 in monocyte and iDC cultures than the other PGAs.

236 itory (DNI) mutant to replace PA in PA or PA-PGA vaccines.

237 els of antibodies against PA and PGA than PA-PGA conjugate.

238 New patient PGA outcomes showed considerable improvement over time.

239 continuously fed with de-esterified pectin (PGA).

240 d the competitive inhibitor phosphoglyolate (PGA) acts as an activator of this variant.

241 brane proteins PgaA and PgaB did not prevent PGA synthesis but did block its export, as shown by the

242 tion, implying that N-deacetylation promotes PGA export through the PgaA porin.

243 l for antigen clearance showed that purified PGA accumulates in the liver and spleen, most notably in

244 patients with psoriasis in clinic, recording PGA scores for each patient.

245 antitative 4-grade scale, named respectively PGA (Physician Global Assessment) and PtGA (Patient Glob

246 le and renal clearance route of the selected PGA-doxy candidate, settling the adequacy of our conjuga

247 L-8 and IL-6 from monocytes, but B. subtilis PGA also elicited IL-10 and TNF-alpha, whereas B. lichen

248 GAs elicited IL-8 from iDCs, but B. subtilis PGA also elicited IL-6, and B. licheniformis PGA elicite

249 B. subtilis PGA and B. licheniformis PGA both elicited more TLR2 sig

250 l than B. anthracis PGA, whereas B. subtilis PGA elicited none.

251 racis PGA, but only responses to B. subtilis PGA were affected by a TLR6 neutralizing Ab.

252 a DeltapgaC mutant, which cannot synthesize PGA.

253 in children and young adults with long-term PGA exposure.

254 e was sensitized to some allergen other than PGA via a route different from that of jellyfish sting.

255 less effectively by innate immune cells than PGAs from nonpathogenic Bacillus species, resulting in f

256 We concluded that PGA protects A. actinomycetemcomitans cells from detachm

257 l, our experimental results demonstrate that PGA-FLUO within an HA-CP penetration enhancer represents

258 Our results demonstrated that PGA is a potent coagulant for the coacervation of 7S, 11

259 Finally, we demonstrated that PGA-FLUO applied within HA-CP effectively reduced psoria

260 tro and ex vivo analyses, we discovered that PGA-FLUO inhibited pro-inflammatory cytokine release, su

261 resent genetic and biochemical evidence that PGA is also a major matrix component of biofilms produce

262 We found that PGA binds to and is internalized by J774.2 cells and acc

263 Finally, we found that PGA is degraded in J774.2 cells starting 4 h after uptak

264 logical functions for PGA and indicates that PGA represents an excellent target for therapeutic maneu

265 Therefore, we propose that PGA serves as an adhesin that stabilizes biofilms of E.

266 g on simulated and real data sets shows that PGA significantly outperforms previous methods, especial

267 The PGA can be readily incorporated into practice to track p

268 The PGA severity scores were analyzed over time, with the hy

269 The PGA severity scores were included on physicians' billing

270 trains, the biofilm of the O antigen and the PGA mutants was dramatically reduced, and it had less ce

271 1) and by 4.2 mm Hg (95% CI, 3.5-4.9) in the PGA group (P < .001).

272 LT group, compared with 84.0% of eyes in the PGA group (P = .008).

273 s in the SLT group compared with 8.0% in the PGA group (P = .05).

274 , 49 patients in the SLT group and 47 in the PGA group completed follow-up.

275 Two patients in the PGA group exited owing to drug-related complications (1

276 he CAT-BM were significant predictors of the PGA scales.

277 czema severity as recalled by parents on the PGA, estimated by the within-patient score change (4.27)

278 y score with the highest R(2) to predict the PGA.

279 ed by bacteria cultivated in the vessel, the PGA is depolymerized into oligogalacturonates (UGA), whi

280 owed moderate correlations (95% CI) with the PGA (0.67 [0.57-0.75] and 0.57 [0.45-0.66], respectively

281 The highest R(2) with the PGA was obtained by scoring WG activity based on the fol

282 e PDAI also correlated more closely with the PGA.

283 related significantly more strongly with the PGA.

284 cells (iDCs) responded differentially to the PGAs, with B. anthracis PGA being least stimulatory and

285 Similarly, all three PGAs elicited IL-8 from iDCs, but B. subtilis PGA also e

286 ndomized to SLT and 50 patients (99 eyes) to PGA medical therapy.

287 adherence rates were calculated for topical PGA use during the 18 months before the introduction of

288 Although underinvestigated, PGA is the most common asthma phenotype in patients with

289 Median unilateral PGA exposure time was 31.7 months (interquartile range:

290 e they perceived to have received unilateral PGA treatment by physical appearance alone and graded th

291 nt had severe PAP after long-term unilateral PGA exposure.

292 e employed; three anchor-based methods using PGA as the anchor: the within-patient score change, betw

293 inhibitor of isopeptidase activity, whereas PGA(1) and PGA(2) with simple alpha,beta-unsaturated pen

294 bset of clinics and dates were compared with PGA scores to assess within-clinic reliability, with the

295 rates and lower IOP reduction compared with PGA therapy in eyes with persistent appositional angle c

296 statistically significant correlations with PGA scores.

297 Forty-five patients with PGA (23 sporadic cases and 22 from familial pedigrees) a

298 airway inflammatory markers in patients with PGA and therefore defining PGA as a potentially "steroid

299 ering effectiveness in clinical studies with PGAs.

300 glaucoma, who were treated unilaterally with PGAs for at least 12 months.